Cargando…
β-secretase inhibition prevents structural spine plasticity deficits in App(NL-G-F) mice
All clinical BACE1-inhibitor trials for the treatment of Alzheimer's Disease (AD) have failed due to insufficient efficacy or side effects like worsening of cognitive symptoms. However, the scientific evidence to date suggests that BACE1-inhibition could be an effective preventative measure if...
Autores principales: | Blume, Tanja, Filser, Severin, Sgobio, Carmelo, Peters, Finn, Neumann, Ulf, Shimshek, Derya, Saito, Takashi, Saido, Takaomi C., Brendel, Matthias, Herms, Jochen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354544/ https://www.ncbi.nlm.nih.gov/pubmed/35936777 http://dx.doi.org/10.3389/fnagi.2022.909586 |
Ejemplares similares
-
BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
por: Peters, Finn, et al.
Publicado: (2018) -
Impact of α‐synuclein spreading on the nigrostriatal dopaminergic pathway depends on the onset of the pathology
por: Sun, Fanfan, et al.
Publicado: (2021) -
Increased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old App(NL/NL) Knock-In Mice
por: Salas, Isabel H., et al.
Publicado: (2018) -
BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines
por: Blume, Tanja, et al.
Publicado: (2018) -
Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer’s disease
por: Zou, Chengyu, et al.
Publicado: (2015)